Evaluating the response and side effects of [۱۷۷Lu]Lu-PSMA therapy in mCRPC patients: A single-center experience from Iran

Introduction: To evaluate clinical and laboratory findings in patients undergoing [۱۷۷Lu]Lu-PSMA treatment for metastatic castration-resistant prostate cancer (mCRPC).Methods: This cross-sectional study included mCRPC patients treated with [۱۷۷Lu]Lu-PSMA. Patients underwent regular evaluations by a nuclear medicine specialist, with laboratory tests (CBC, serum PSA, creatinine, and liver functions) conducted before each treatment cycle and at ۱-, ۴-, and ۸-weeks post-treatment. Treatment cycles were repeated every ۸-۱۰ weeks to assess response and side effects. Patients received [۱۷۷Lu]Lu-PSMA intravenously, followed by a ۶-hour monitoring period. A pre-designed checklist was used to collect demographic data, clinical manifestations (pain assessment via VAS), treatment complications, and laboratory parameters. The relationships among PSA level changes, age, and radiopharmaceutical dosage were analyzed, along with side effects related to blood cell counts and serum creatinine levels.Results: This study evaluated the efficacy and safety of [۱۷۷Lu]Lu-PSMA treatment in ۱۳۳ metastatic castration-resistant prostate cancer (mCRPC) patients. PSA level decreases in ۱۲۲ patients (۹۲%), with ۳۹ (۲۹%) achieving a ≥۵۰% reduction. Disease stabilization occurred in ۷۹ patients (۵۹%), while ۳۴ patients (۲۶%) experienced disease progression. Bone pain relief in ۴۱% of ۷۲ patients complaining of baseline pain. Hematological toxicity was observed mostly as grade ۱ (۶۷%) and as grade ۲ (۳۴%) of the patients. No renal or hepatic complications were observed.Conclusion: The results suggest that [۱۷۷Lu]Lu-PSMA treatment is effective in managing metastatic castration-resistant prostate cancer, with a favorable therapeutic response and limited side effects.

کلیدواژه ها:

Radioligand therapy ، [۱۷۷Lu]Lu-PSMA ، prostate cancer ، mCRPC